Articles by Graham Clarke - BioPharm International

Articles by Graham Clarke

Cell-Culture–Based Manufacturing: Meeting the Challenge of 21st Century Influenza

Influenza vaccines traditionally required yearly redevelopment to address changes in flu strains. With breakthrough technologies, however, the variables of yearly redevelopment can be reduced—accelerating time to market while reducing costs.
Aug 2, 2007
By: Amanda Shipman, Graham Clarke

Vaccines against strains originating from avian flu may achieve poor yields in egg-based systems. Consequently, both public and private interest in alternative systems is high.